首页|靶向泛素特异性蛋白酶1小分子抑制剂的研究进展

靶向泛素特异性蛋白酶1小分子抑制剂的研究进展

扫码查看
泛素特异性蛋白酶1(ubiquitin-specific protease 1,USP1)是在癌症研究中越发受关注的去泛素化酶之一。USP1在许多肿瘤中过度表达,现已发现USP1能通过调控与肿瘤相关的多种蛋白质的表达来控制肿瘤的发生和进展,如SIK2、GSK-3β和Bcl-2等。基因敲除或药物抑制USP1能有效抑制肿瘤,同时还有望解决顺铂以及聚腺苷二磷酸核糖聚合酶(poly ADP-ribose polymerase,PARP)抑制剂耐药性问题。本综述介绍了 USP1的结构、功能以及USP1靶点与肿瘤的关系,并系统地总结2013年至2023年公开的USP1小分子抑制剂的结构、活性以及构效关系。最后,本综述讨论了开发USP1小分子抑制剂的挑战和机遇。
Advances in developing small molecule inhibitors of ubiquitin-specific protease 1
Ubiquitin-specific protease 1(USP1)is one of the deubiquitinating enzymes which has received increasing attention in cancer research.USP1 is overexpressed in many types of cancer cells,and has been found to control tumorigenesis and progression by regulating various proteins associated with tumors,such as SIK2,GSK-3β,and Bcl-2.Knockdown or pharmacological inhibition of USP1 can effectively suppress tumors and is also expected to address the issues of cisplatin and poly ADP-ribose polymerase(PARP)inhibitor resistance.This review describes the structure and function of USP1 and the relationship between USP1 targets and tumors and systematically summarizes the structure-activity relationships of small molecule USP1 inhibitors disclosed from 2013 to 2023.Finally,this review discusses the challenges and opportunities in developing small molecule USP1 inhibitors.

ubiquitin-specific protease 1small molecule inhibitorsynthetic lethalitydrug resistancestructure-activity relationship

徐嘉浩、李宏瑞、把睿先、刘同超、熊兵

展开 >

江西中医药大学药学院,江西南昌 330004

中国科学院上海药物研究所,上海 201203

长三角药物高等研究院,江苏南通 226133

沈阳药科大学,辽宁沈阳 110016

展开 >

泛素特异性蛋白酶1 小分子抑制剂 合成致死 耐药性 构效关系

国家自然科学基金

82204187

2024

药学学报
中国药学会 中国医学科学院药物研究所

药学学报

CSTPCD北大核心
影响因子:1.274
ISSN:0513-4870
年,卷(期):2024.59(4)
  • 85